Oslo, Norway, November 24, 2021 - Nykode Therapeutics (formerly Vaccibody*))
(Euronext Growth (Oslo): VACC) refers to the announcement made on November 23,
2021 regarding the execution of a multi-target license and collaboration
agreement with Regeneron.
In accordance with the agreement and as described in the initial announcement,
the board of directors of Nykode Therapeutics has today resolved to issue
2,255,034 new shares to Regeneron at a price of NOK 79.07 per share, based on a
resolution to increase the share capital granted by the annual general meeting
on May 5, 2021.
Following registration of the share capital increase related to the share issue,
the share capital of Nykode Therapeutics will be NOK 2,895,027.44, divided into
289,502,744 shares, each with a par value of NOK 0.01.
*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS,
has called for an EGM on November 30, 2021, to vote for the approval of the
change of its company name from Vaccibody AS to Nykode Therapeutics AS.